GLP‑1 Drugs: Benefits, Risks, and New Frontiers

Here’s a formatted list of the references provided,suitable for a bibliography or works cited page. I’ve maintained the original formatting as much as possible.

References

1. Centers for Disease Control and Prevention. alcohol Use and Health. Published december 8, 2023. Accessed December 9, 2025. https://www.cdc.gov/alcohol/index.htm
2. National Institute on Alcohol Abuse and Alcoholism (NIAAA). Alcohol Facts. Published November 2023. Accessed december 9, 2025. https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/alcohol-facts
3. Keyes KM, Cerdá M, Hasin DS, et al. The relationship between alcohol use and suicidal behavior in the United States, 2008-2018. JAMA Netw Open. 2020;3(12):e2025983. doi:10.1001/jamanetworkopen.2020.25983
4. Grant BF, Chou PS, Saha TD, et al. Prevalence of 12-month alcohol use, heavy drinking, and dependence in the US adult population: 2009-2014. JAMA Psychiatry. 2017;74(9):895-904. doi:10.1001/jamapsychiatry.2017.1683
5. National institute on Alcohol abuse and Alcoholism (NIAAA). Treatment for Alcohol Problems. Published November 2023. Accessed December 9, 2025. https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/treatment-alcohol-problems
6. National Institute on Drug Abuse (NIDA). Medications to Treat Alcohol Use Disorder. Published November 2023. Accessed December 9, 2025. https://nida.nih.gov/drug-topics/alcohol-use-disorder/medications-to-treat-alcohol-use-disorder
7. U.S. Food and Drug Administration. FDA approves Wegovy for chronic weight management. News release. December 4, 2022. Accessed December 9, 2025. https://www.fda.gov/news-events/press-announcements/fda-approves-wegovy-chronic-weight-management
8. U.S. Food and Drug Administration. FDA approves Ozempic for chronic weight management. News release. December 8, 2023. Accessed December 9, 2025. https://www.fda.gov/news-events/press-announcements/fda-approves-ozempic-chronic-weight-management
9. Powers AC, et al. Diabetes Care. 2023;46(Suppl 1):S1-S264.
10. shafi T,et al.MMWR Morb Mortal Wkly Rep.2023;72(44):1269–1272. doi:10.15585/mmwr.mm7308a1
11. Manthey J, Shield KD, Rylett M, Hasan OSM, Probst C, rehm J. Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study. Lancet. 2019;393(10190):2493-2502. doi:10.1016/S0140-6736(18)32744-2
12. Hendershot CS, Bremmer MP, Paladino MB, et al. once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025;82(4):395-405. doi:10.1001/jamapsychiatry.2024.4789
13. Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med. 2025;31(3):951-962. doi:10.1038/s41590-024-03412-w
14. Du H, Meng X, Yao Y, xu J. The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease. Front Endocrinol (Lausanne). 2022;13:1033479. doi:10.3389/fendo.2022.1033479
15. Perry TA, Greig NH. The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer’s disease. J Alzheimers Dis. 2002;4(6):487-496. doi:10.3233/jad-2002-4605
16. Cummings JL,Atri A,Feldman HH,et al. evoke and evoke+: design of two large-scale,double-blind,placebo-controlled,phase 3 studies evaluating efficacy,safety,and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease. Alzheimers Res Ther. 2025;17(1):14. doi:10.1186/s13195-024-01666-7
17. Alzheimer’s Association Statement on Oral Semaglutide Phase 3 Topline Data release. News release. Alzheimer’s Association. November 24, 2025. Accessed December 9, 2025. https://www.alz.org/news/2025/alzheimers-association-statement-oral-semaglutide-phase-3-topline-data-release
18. Vijaratnam N, Girges C, Auld G, et al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson’s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomized, placebo-controlled trial. Lancet. 2025;405(10479):627-636. doi:10.1016/S0140-6736(24)02808-3
19. de Souza PC, Bezerra TPW, Rêgo MJB, da Rosa MM. Advanced in neurological therapies: a review of clinical trials in Alzheimer’s, Parkinson’s, and multiple sclerosis.Am J Med. 2025;S0002-9343(25)00826-5. doi:10.1016/j.amjmed.2025.11.025
20. Meissner WG, Remy P, Giordana C, et al.Trial of lixisenatide in early Parkinson’s disease. N Engl J med. 2024;390(13):1176-1185. doi:10.1056/NEJMoa2312323
21. Morais BAAH, Prizão VM, de Souza MM, et al. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: a meta-analysis of randomized controlled trials. J Diabetes Complications. 2024;38(10):108834. doi:10.1016/j.jdiacomp.2024.108834
22. Bo Y, Zhao J, Liu C, Yu T. Comparative efficacy of pharmacological interventions on metabolic and hormonal outcomes in polycystic ovary syndrome: a network meta-analysis of randomized controlled trials. BMC Womens Health. 2025;25(1):64. doi:10.1186/s12905-025-03594-6
23. Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. endocrinology. 2014;155(4):1280-1290. doi:10.1210/en.2013-1934

Note: I’ve assumed a standard citation style (similar to APA or MLA) for formatting. If you need a specific style (Chicago, Vancouver, etc.), please let me no, and I can adjust the formatting accordingly. Also, please double-check all DOIs and URLs for accuracy.